RudaCure took part in the 24th InterBiz Bio-Partnering & Investment Forum 2026 (InterBiz 2026), held July 1–3, 2026 at Phoenix Island Jeju, running a full schedule of partnering meetings.
At the forum, RudaCure sat down with 27 teams to discuss partnering and collaboration opportunities. Though each meeting was brief, the interest shown in RudaCure's drug candidates and the insights shared by every team helped us picture, in far more concrete terms, what we could build together.
RudaCure extends its sincere gratitude to the many teams that explored ways to strengthen the areas where the company is weaker; to those who took a genuine interest in RudaCure's drug candidates, considered how to actively apply them, candidly pointed out our gaps and shared where we could improve; to those who agreed on a win-win strategy through open innovation and searched for the path forward together; and to every team that gave their valuable time to meet with us.
The partners who joined RudaCure at InterBiz 2026 are as follows:
대웅제약 · 동아쏘시오홀딩스 · GC녹십자웰빙 · 삼성바이오로직스 · 알테오젠 · 아토매트릭스 · 국제약품 · 대원제약 · 신신제약 · 신일제약 · 한국비엠아이 · 제뉴원사이언스 · JW생명과학 · 티온랩테라퓨틱스 · 큐리오사바이오사이언스 · 제닉스큐어 · 센서디스커버엑스 · 링크씨코리아 · 메디톡스벤처투자 · BIP FOCUS · 한양대학교 에리카 산학협력단 · 글로벌 TOP 유전자·세포치료 전문연구단 · 경보제약 · 한미정밀화학 · 다래사업화전략센터 · 인천창조경제혁신센터 · 마더스제약
RudaCure plans to follow up with each team soon so that these conversations do not end as a one-time greeting. We look forward to your continued interest in RudaCure's next chapter.